AWTTC is currently reviewing AWMSG processes which support medicines access in NHS Wales. As the medicines access landscape across the UK is changing, we are adapting our processes to ensure routes of access to medicines in Wales meet the needs of patients, healthcare professionals and the NHS in Wales. Our review is ongoing and we will provide an update by Spring 2024.
In the meantime we encourage companies to send any enquiries relating to submissions for medicine appraisal to us at AWTTC@wales.nhs.uk. Alternatively, companies can provide information regarding planned medicine launches by completing and submitting a Form A.
For further information please see our Review of AWMSG processes to support medicines access in NHS Wales document.
We aim to give advice about all licensed medicines meeting our appraisal criteria within 6–9 months of the medicine receiving its licence. Information about the stages of an AWMSG appraisal and the documentation needed for each stage are given below.
After receiving your Form A, we will confirm if your medicine meets AWMSG’s criteria for appraising it as a full submission (Form B) or a limited submission (Form C). If your medicine doesn't meet AWMSG's criteria for appraisal then we will inform you that the medicine is 'excluded from HTA' and will not be appraised. Without a submission (Form B or Form C), there are two courses of action AWMSG may take: